Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Pfizer (NYSE: PFE) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Pfizer's business and see what CAPS investors are saying about the stock right now.

Pfizer facts

Headquarters (Founded)

New York City (1849)

Market Cap

$140 billion



Trailing-12-Month Revenue

$50 billion


CEO Jeffrey Kindler (since 2006)
CFO Frank D'Amelio (since 2007)

Return on Capital (Average, Past 3 Years)


Cash / Debt

$26 billion / $48.7 billion

Dividend Yield



Merck (NYSE: MRK)
GlaxoSmithKline (NYSE: GSK)
Eli Lilly (NYSE: LLY)

Other Highly Rated Drug Stocks

Johnson & Johnson (NYSE: JNJ)
AstraZeneca (NYSE: AZN)
Abbott Labs (NYSE: ABT)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 90% of the 5,738 members who have rated Pfizer believe the stock will outperform the S&P 500 going forward. These bulls include All-Star BSHumphreyII, who is ranked in the top 10% of our community, and dumberthanafool.

Just last week, BSHumphreyII tapped the stock as a healthy way to earn some income: "This is a pure Dog of the Dow pick. Pfizer is currently at a 4.1% dividend yield and an 8.1 future P/E. Pfizer isn't going anywhere, and that's an awfully low P/E for the Pharm sector. They'll outperform the S&P no matter which way the index goes."

In a pitch from last month, dumberthanafool elaborates:

The recent dividend cut was to fund an acquisition, not because of huge business problems. The yield is a rockin' 4%, with an OK, not great, payout ratio. Current ratio is great. Debt is OK. The stock is cheap because of the perception that [Pfizer] does not get a good return on its research dollars, and because of looming patent expirations. In light of recent acquisitions, I think these concerns are overblown.

What do you think about Pfizer, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick. Johnson & Johnson is a choice of Income Investor, and Motley Fool Options has recommended a buy calls position on it. The Fool owns shares of Glaxo. The Fool's disclosure policy always gets a perfect score.